-+ 0.00%
-+ 0.00%
-+ 0.00%

Ascentage Pharma publishes 2025 annual report

PUBT·04/27/2026 23:13:26
Listen to the news
Ascentage Pharma publishes 2025 annual report
  • Ascentage Pharma annual report for year ended Dec. 31, 2025 highlighted expanded commercialization in China for Olverembatinib following NRDL coverage.
  • Lisaftoclax entered commercial market in China in July 2025 for previously treated CLL/SLL patients, supporting shift to a dual-product growth strategy.
  • Company advanced global late-stage development, citing FDA and EMA clearances for Phase III registrational studies in first-line Ph+ ALL for Olverembatinib and higher-risk MDS for Lisaftoclax.
  • Capital base strengthened through NASDAQ IPO on Jan. 28, 2025 raising net proceeds of about US$ 132.5 million.
  • Follow-on HKEX top-up subscription on July 17, 2025 generated net proceeds of about US$ 190.1 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascentage Pharma Group International published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260428-12126947), on April 27, 2026, and is solely responsible for the information contained therein.